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Abstract: Pulmonary fibrosis is the end point ofa chronic
inflammatory process characterized by leukocyte recruit-
ment and activation, fibroblast proliferation, and in-
creased extracellular matrix production. Previous
studies ofmodels ofpulmonary fibrosis have investigated
the role of cytokines in the evolution of the fibrotic
response. The involvement of tumor necrosis factor and
interleukin-1 in bleomycin-induced lung injury, a model
of idiopathic pulmonary fibrosis, has been well estab-
lished, suggesting that cytokines mediate the initiation
and maintenance of chronic inflammatory lesions. How-
ever, the aforementioned cytokines alone cannot account
for the recruitment and activation of specific leukocyte
populations found in the bleomycin model. Recently, a
family of novel proinflammatory cytokines (chemokines)
was cloned and characterized, yielding many putative
mediators ofleukocyte functions. Macrophage inflamma-
tory protein-la (MIP.la) and monocyte chemoattractant
protein-i (MCP-1) belong to the C-C chemotactic cytokine
family, a group of low-molecular-weight peptides. These
molecules modulate chemotaxis, proliferation, and cy-
tokine expression in leukocyte subsets. Our group has
investigated the roles of MCP-i and MIP-la in the
bleomycin model. Both MCP-1 and MIP-la are expressed
in a time-dependent manner after bleomycin challenge,
and passive immunization of these animals with either
anti-MIPla or anti-MCP-1 antibodies attenuated leuko-
cyte accumulation. In addition, we have identified spe-
cific cell types expressing MCP-1 or MIP-la by in situ
hybridization and immunohistochemical localization, re-
spectively. Furthermore, our results indicate that MIP-la
expression is mediated by alveolar macrophage-derived
tumor necrosis factor, identifying an important cytokine
pathway in the initiation of pulmonary fibrosis. Finally,
anti-MIP-la therapy attenuated fibrosis, providing direct
evidence for its involvement in fibrotic pathology. Our
work has clearly established that the C-C chemokines
MCP-1 and MIP-la are expressed and contribute to the
initiation and maintenance ofthe bleomycin-induced pui-
monary lesionJ. Leukoc. Biol. 57: 782-787; 1995.
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INTRODUCTION
Bleomycin sulfate, a dmug used for the treatment of van-
ous nialignancies, is a group of copper-containing, sul-
fated glycopeptides possessing significant antibiological
activity. A side effect of bleomycin administration is acute
pncumonitis, is’ith a small fraction of these patients pro-
giessing to chronic pulmonary fibrosis, a condition re-
sembling idiopathic pulmonary fibrosis (IPF) [1, 2]. In
rodents, bleomycin administration results in a route-,
dose-, and strain-dependent pulmonary inflammatory re-
sponse [3-6]. Given intratracheally, this response is char-
acterized by increases in leukocyte accumulation,
fibroblast proliferation, and collagen content [7, 8]. Ro-
dents challenged with bleomycin typically develop acute
alveolitis 2-3 days postchallenge, followed by intense in-
terstitial inflammation at 4-12 days [9-12]. Fibroblast
proliferation and extracellular matrix synthesis is initiated
4- 14 days postbleomycin challenge and collagen content
is elevated approximately twofold, 3 weeks postchallenge
[4-6, 10, 12]. Beyond 3 weeks postchallenge, fibrosis pro-
gresses, compromising respiratory function, resulting in
significant morbidity in the animal. The rodent pulmo-
nary inflammatory response to intratracheal bleomycin
challenge constitutes a representative model of human
IPF.
Since the initial characterization of the rodent model in
1974, many soluble mediators have been implicated in the
pulmonary response to intratracheal bleomycin challenge
[7, 13]. Bleomycin has been shown to induce free radical
formation, resulting in lung lipid peroxidation and injury
[14, 15]. Other putative soluble mediators are arachidonic
acid metabolites. Inhibition of cyclooxygenase with in-
domethacin or inhibition of lipoxygenase with nordihy-
droguiaretic acid attenuated the fibrotic lesion,
suggesting a role for the products of these pathways [16,
1 7]. Subsequent studies identified fibroblast growth-pro-
moting factors from the lavage fluid and alveolar macro-
phage culture supernatants of bleomycin-challenged
animals. One of these factors, originally characterized as
macrophage-denived growth factor, is probably a combi-
nation of tumor necrosis factor-a (TNF-a), interleukin-i
(IL-i), IL-6, transforming growth factor-n (TGF-), plate-
let-derived growth factor (PDGF), and other growth fac-
tons [13]. Various in vitro studies have identified
fibroblast growth factor, TNF-a, and PDGF as potent in-
ducers of fibroblast proliferation [18]. In contrast, other
in vitro work has identified TGF-3 as both an inhibitor
and promoter of fibroblast proliferation, this disparate
effect being dependent on the concentration of the cytok-
me and the source of the target cells [13, 18-20]. Further-
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more, PDGF and TGF43 have been shown to induce col-
lagen mRNA, whereas IL-i is believed to increase colla-
gen content via inhibition of collagenase activity [13].
In vivo time-dependent expression of TNF and IL-i
mRNA has been detected in whole lung and bron-
choaveolar lavage preparations [12, 21, 22]. Initial expres-
sion of these mediators 3-8 days postbleomycin challenge
precedes proliferation of fibroblasts and induction of col-
lagen synthesis, which peak in the 2nd week. Interest-
ingly, neutralization of TNF with anti-TNF antibodies or
soluble TNF receptors abrogates the pulmonary fibrotic
response in mice [12, 23]. Similarly, continuous intnavC-
nous infusion of bleomycin-challenged mice with IL-i re-
ceptor antagonist protein resulted in a moderate
reduction of fibrosis [24]. These results suggest that me-
diators such as TNF and IL-i, present in the 1st week
postchallenge, have a role in the initiation of the lesion.
Attenuation of the bleomycin-induced lesion after the in-
hibition of these distinct inflammatory mechanisms mdi-
cates that this response involves many different
interdependent pathways by using a diverse milieu of
soluble mediators.
The inflammatory response to bleomycin challenge
may be described temporally by the appearance of differ-
ent leukocyte subsets within the lungs. In mice and rats
neutrophil accumulation peaks around 2 days postchal-
lenge [9, 10]. Eosinophilic lung infiltrates have been ob-
served 7 days postchallenge in both iats and hamsters [9,
11, 16, 25]. Bleomycin-challenged, mast cell-deficient, on
neutrophil-depleted mice developed pulmonary fibrosis,
despite these cellular deficiencies [26, 27]. In contrast to
granulocytes, significant increases in mononuclear phago-
cytes are not observed until 4 days postchallenge, peaking
at 8-14 days, depending on the dose of bleomycin and
the strain ofanimal [9, 10]. Lung macrophages have been
shown to produce anachidonic acid metabolites and neac-
tive oxygen species, as well as TNF-a and IL-i protein, on
direct stimulation with bleomycin, underlying the impon-
tance of these cells to the development of the lesion [28,
29]. Elevated lymphocyte counts have been observed in
lavage fluid as early as 2 days postchallenge and after 8
days the total lymphocyte count in the lungs approxi-
mates untreated controls [10, 25, 30]. Furthermore,
bleomycin-challenged nude mice have diminished fibrosis
compared with positive controls, and more recent CD4
and CD8 T lymphocyte depletion studies demonstrated
abrogation of pulmonary fibrosis [12, 31]. In summary,
these results suggest a central role for macrophages and
lymphocytes, and little, if any, for neutnophils and mast
cells, in the development of bleomycin-induced pulmo-
nary pathology.
C-C chemokines: novel proinflammatory polypeptides
Recruitment of leukocytes is an essential step in the de-
velopment of any inflammatory lesion. In small venules
leukocytes bind endothelium via the expression of adhe-
sion molecules on both leukocytes and endothelial cells.
Adherent leukocytes extravasate out of the vascular corn-
partment and migrate through the basement membrane
and extracellulan matrices to the site of inflammation.
Once at the inflammatory lesion, recruited leukocytes
modulate the host response in a stimulus-specific manner
by cell-to-cell interactions and secretion of soluble media-
tons. The recruitment of leukocytes by the aforemen-
tioned processes is currently an area of intense scrutiny.
Recently, a family of novel proinflammatory cytokines has
been cloned antI characterized, yielding many putative
mediators of macrophage-, lymphocyte-, and granulocyte-
derived responses in disease models [32, 33]. The C-C
chemokine supengene family includes macmophage in-
flammatory protein-ia (II P- la), MI P- 1 , RANTES,
monocyte chemoattnactant protein-i (MCP-i), MCP-2,
MCP-3, HC-14, Gb, and 1-309. C-C chemokines, grouped
on chromosome 17, are so named because of the juxtapo-
sition of the first tss’o cysteine residues at the NH2-termi-
nal. Originally described as chemotactic factoms, C-C
chemokines also modulate cytokine production, adhesion
molecule expression, and mononuclear cell prolifeiation
[34-37]. Although m4 and lymphocytes are the predomi-
nate cell types targeted, members of this family possess
differential chemotactic and stimulatory activity for spe-
cific leukocyte subsets.
MIP-la and MCP-1
MIP-i was originally described as a 16-kDa lipopolysaccha-
ride-inducible hepanin-bimiding dipeptide (MIP-la and -
i3) with leukocyte chemotactic activity [38]. In vitro
studies have shown that MIP-la is chemokinetic for neu-
trophils and chemotactic for mononuclear phagocytes,
basophils, and subsets of lymphocytes [38-40]. MIP-la
preferentially mediates chemotaxis of CD8 lymphocytes
compam’ed \Tith CD4 lymphocytes, whereas the reverse is
true for MIP-i3 [40]. Appropriately stimulated T lympho-
cytes, alveolar and penitoncal macrophages, neutrophils,
monocytes, airway epithelial cells, and fibroblasts have
been identified as cellular sources ofMIP-la protein [10,
41-46]. MIP-la stimulates IL-i, IL-6, and TNF production
from penitoneal macmophages and MIP-la protein expres-
sion from mononuclear cells is stimulated in vitro by
lipopolysacchanidc and IL-i [34, 43, 46].
Initially characterized as theJE gene, MCP-1 is a glyco-
sylated, 14- to 25-kDa pmotein cloned from PDGF-stimu-
lated munine 3T3 cells [47]. Subsequent in vitro studies
demonstrated stimulus-specific induction of MCP-i
mRNA from human fibroblasts and endothelial cells [48].
Originally described for its monocyte chemotactic activ-
it)’, MCP-1 is a more potent chemoattractant for lympho-
cytes in vitro [49]. In addition, MCP-i possesses
chemotactic activity for basophils but not foi neutrophils
[39]. Peritomieal macrophages, lymphocytes, smooth mims-
dc cells, epithelial cells, enclothelial cells, and vaiious
transformed cell lines have been reported to secrete
MCP-1 protein in the presence of sei-um or specific stim-
uli [32, 50]. MCP-1 stimulates the expmession of IL-6 and
IL-i fi’om peripheral blood niononuclean cells but has no
effect on TNF expression [35].
In vivo MCP-i and MIP-la contribute to acute and
cellular immune tissue responses via recruitment and ac-
tivation of mononuclear phagocytes and T lymphocytes.
Elevated I’siIP-ia has been nieasumcd as early as 6 11
postlipopolysacchanide challenge in the lungs of CD-l
mice and elevated MCP-1 expression has been reported
at early time points in a model of dermal wound icpain
[ 36, 51]. Passive immunization of granuloma-beaning
CBA/J mice with either anti-MIP-la or anti-i’sICP-l anti-
bodies decreased the size and ccllulamity of the inflamma-
tory granulomatous lesion [52, 53]. These results piovidc
evidence that increases in MCP-1 amid MIP-la expression
comitribute to the development of both acute and chronic
inflamiimiiatory lesions.
6h 24h 2d 4d 8d 12d 16d
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The clinical diagnosis of IPF is based on the presence of
dyspnea, a radiographic profusion scone, and pulmonary
function tests. Consequently, because diagnosis is made
after the onset of findings caused by fibrotic pathologies,
studies of the initiation of the fibrotic lesion have been
difficult in humans. Nevertheless, analysis of bron-
choalveolan lavage and open lung biopsies from patients
who meet the diagnostic criteria for IPF has indicated
elevated levels of MCP-i and MIP-la protein compared
with healthy volunteers. In addition, anti-MCP-i and anti-
MIP-la antibodies inhibited 22% and i8%, respectively,
of the miiononuclean cell chemotactic activity in lavage
fluid [41]. Fibroblast cultures gmown out of fibrotic re-
gions obtaimied by open lung biopsies from IPF patients
constitutively secreted significant levels of MCP-i and
MIP-la protein. In contrast, normal fibroblast cultures
derived fiom the tissue ofnormal regions oflungs did not
express chemokines in a similar manner [4i]. This result
indicates that the initial inflammatory processes in IPF
may promote fonmuiation of an altered phenotype of lung
fibroblasts.
C-C chemokine expression in the bleomycin model
Rodent models have previously been evaluated at latem
time points (3 weeks) posthleomycin challenge, providing
information on the maintenance stage of the fibrotic le-
sion. However, recent rodent studies have focused on the
involvemnent of C-C chemokines imi the early stage (3
weeks) after bleomycin administration, providing imifon-
mation omi the initiation of the fibrotic lesion [54]. Time-
dependent expression of MCP-i mRNA has beemi
reported in response to bleomycin challenge in rats (Ta-
ble 1). MCP-i mRNA extracted from alveolar lavage cells
peaked at 24 Ii postchallcnge, whereas the signal from
whole lung homogenates peaked at 7 days, correlating
with eosinophil, lymphocyte, and mononuclear phago-
cytes accumulation [25]. Interestingly, similar to MCP-i,
TNF and IL-i protein are differentially expressed by a!-
veolar and interstitial macrophages isolated from bleomy-
cm-challenged mice, providing a putative cellular basis for
the compartment-specific expression of MCP-1 protein
[21].
In CBA/J mice we have observed elevated MCP-i pro-
tein i, 2, and 4 days postchallenge in whole lung homo-
genates, with little on no detectable increases at 8-21 days
(Table 1). In addition, we have measured elevated MCP-i
protein 2 days postchallenge in bronchoalveolan lavage
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Fluid (BALF). Similai to the compartment-specific expres-
sion in the rat, MCP-i is elevated in whole lung homogen-
ates but not in lavage fluid 4 clays postbleomycin
challenge (unpublished observations). NIIP-ia protein
and mRNA (Fig. 1) expression in lung homogenate
preparations was elevated at 1, 2, 8, 12, and i6 days
postchallenge, with detectable antigen peaking at 2 and
16 clays (Table 1) [10]. In contrast to MCP-i, the kinetics
of whole lung MIP-la expression approximated the ex-
pression in BALF. In the munimie model the kinetics of
expression of MIP-ia and MCP-i during the 1st week
postchallenge coincide temporally with the accumulation
and trafficking of lymphocytes and mononuclear phago-
cytes, which are first elevated at 2 amid 4 days, respectively.
In the 2nd week postchallenge, dIP-1a expression coin-
cides with large increases in rnomionuclear phagocytes,
%.,Theneas elevated MCP-1 expression is not observed at this
time. These data and the previous findings in the rat
provide circumstantial evidemice for MCP-i and MIP-ia
acting as chemotactic factoms in vivo.
Although the above data are imitiiguing, they do not
provide direct evidence for the actual functions of MCP-i
and MIP-ia in vivo. Neutralization of these chemokines
during the response to blcomycin has yielded interesting
results. Passive immunization of CBA/J mice with anti-
MCP-i (unpublished observations) or anti-MIP-ia anti-
bodies reduced total lung inflammatory cell content by
30% and 35%, respectively [10]. Differential analysis mdi-
cated meduction of mononucleai cells by anti-MCP-i,
whereas both mononuclear phagocytes and, to a lessen
extent, gnanulocytes were decreased after anti-MIP-la
tmeatment. Consistent with these results, anti-MIP-la ne-
duced the total number of Mac-i (CDI ib)-positive stain-
ing cells compared with positive contiols (Table 2). These
results are comisistent with the mepoiiecl in vitro chemotac-
tic activities of both r’s’ICP-i amid N’IIP-ia and with the
specific chemotactic activities attributed to these chemok-
ines in the lavage fluid of IPF patients.
Roles for mononuclear phagocytes and lymphocytes in
the blconiycimi model have been clearly established. Less
well characterized, however, is the molc of B cells. Immune
complex deposition comitnibutes significantly to the patho-
logical processes obsemxccl in IPF but has not been well
evaluated in the rodent niodel. hi bleoniycimi-challenged
mice ve have detected incieascs in cells labeling positive
for the B220 antigen, a niaikei fon B cells (Table 2).
Interestingly, passive immunization of challenged mice
with amiti-MIP-la antibodies decmeased the fraction of lym-
phocytes staining positive for B220 fm’om 42% to 36%
MIP-la
cyclophilin
Fig. 1. Detection of ele-ated NIIP-la n1RNA b’ reverse transcription-pa-
iymerase chain reaction in Wilole lung homogenates fionl CILA/J mice 6
h to 16 (lays postbleonlvein challenge.
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(data not showmi), corresponding to a net decrease of
approximately one million cells per animal (Table 2).
These results suggest that MIP-la mediates B cell accumu-
lation during bleomycin-inducecl lung injury.
Chemotaxis may not be the only proinflammatory
mechanism attributed to MIP-la and MCP-i in vivo. Re-
cent work suggests MIP-ia modulates intercellular adhe-
sion molecule-i expression, whereas MCP-i can stimulate
dose-dependent expression of CD1 ib and CD1 ic on the
surface of peripheral blood monocytes, suggesting that
cheniokines promote adhesion events in vivo [35, 36]. In
addition, penitoneal macrophages proliferated in vitro
when exposed to MIP-ia alone or to MIP-ia with colony-
stimulating factor-i on granulocyte-macnophage colony-
stimulating factor [37]. Although the precise mechanisms
are unknowmi, the above results indicate that MCP-i and
MIP-la contribute to the processes of leukocyte accumu-
lation in the bleomycin-induced pulmonary fibrosis
model.
Identification of cellular sources of C-C chemokines in
vivo
Many in vitro studies have identified cellular sources of
C-C chemokines. More important, howeven, is detenmin-
ing which cell type(s) are sources in vivo. Alveolar macro-
phages from bleomycin-challenged mice have been
identified as a possible cellular source of MCP-i by immu-
nohistochemical localization (unpublished observations).
Also, in the munine model, alveolar macnophages, airway
: epithelial cells, and interstitial macrophages stained posi-
 tive for MIP-ia antigen [10]. Alveolar macnophages were
. positive for MIP-ia as early as 24 h postchallenge,
 whereas interstitial macrophages were not positive until
day 8, correlating with the progression of the disease
process from the alveolar to the interstitial space. Re-
cently, eosinophils were identified as a potential source of
MCP-i by in situ hybridization [25]. In the rat lung eosi-
nophils accounted for 85% of MCP-i-positive cells 7 days
postbleomycin challenge. Peaking at day 7, MCP-i-posi-
tive eosinophils persist throughout the proliferative phase
(2nd week) of the lesion. This result establishes an impor-
tant cellular source of MCP-1 and argues that eosinophils,
unlike neutnophils and mast cells, potentially have a role
in the evolution of the fibrotic response.
The identification of eosinophil participation in the rat
bleomycin lesion pmovides an in vivo basis for recent re-
cepton studies pemfonmed on the human eosinophilic HL-
60 cell line. Butynic acid induced expression of a RANTES
and MIP-ia dual receptor omi differentiated HL-60s, and
this receptor mediated chemotactic Ca2 flux and respira-
tory burst responses [55]. Complementing this result, our
lab has recently demonstrated that MIP-ia mediates eos-
inophil accumulation in a munine model of airway hyper-
activity [44]. Although complete investigations have yet to
be conducted in the same model, these data provide a
mechanism for eosinophil recruitment and participation
in chronic inflammatory processes.
Fibroblast-derived C-C chemokines in the
bleomycin-induced lesion
The 2nd week of postbleomycin challenge is the period in
which increases in fibnoblast proliferation and collagen
mRNA occur. Recently, cells with a myofibroblast pheno-
type, as determined by expression of a-smooth muscle
actin, were shown to be the predominate cell type respon-
sible for procollagen mRNA expression 7-14 days
postchallenge [56]. In related experiments, a-smooth
muscle actmn-positive cells were also positive for MCP-i
mRNA [25]. These results identify a potential target for
profibrotic stimuli within the bleomycin lesion. Consis-
tent with this conclusion, our lab has isolated C-C
chemokine-secreting, fibroblast-like cells from schis-
tosoma egg-induced liven gmanulomas [43]. These cells
constitutively expressed MCP-l mRNA and protein,
whereas MIP-la mRNA and protein was expressed in a
stimulus-specific manner. These results indicate that fi-
broblasts from rodent models of chronic inflammation
appear to have an altered phenotype, similar to fibroblast
explants from IPF patients.
Fibroblast-denived MCP-i on MIP-ia may have several
different functions in the fibrotic lesion. Although there
is no evidence indicating that MCP-i or MIP-la directly
induce fibroblast proliferation or collagen synthesis, they
could be competence factors for these activities in vivo.
In addition, fibroblast-denived C-C chemokines may con-
tribute to the maintenance of the fibrotic lesion by initi-
ating mononuclear cell accumulation and by modulating
expression ofprofibrotic mediators from the surrounding
granulation tissue. To evaluate these putative mecha-
nisms, we passively immunized CBA/J mice with anti-
MIP-ia antibodies and measured hydroxyproline content
2 i days postbleomycin challenge. Bleomycin-challenged
mice treated with anti-MIP-la antibodies demonstrated a
49% decrease in lung hydroxyproline compared with
bleomycin-challenged mice treated with preimmune Se-
rum [iO]. These results support the notion that C-C
chemokines participate in the fibrotic process, possibly by
inducing leukocyte accumulation and activation.
Cytokine networks mediate the response to bleomycin
Several studies have illustrated a central role for TNF in
the munine bleomycin model. Nevertheless, linkage of
TNF expression and specific leukocyte recruitment has
not been previously demonstrated. We were able to de-
tect bioactive TNF but not MIP-ia in lavage fluid of mice
6 h after bleomycmn challenge (unpublished observations).
Furthermore, elevated TNF protein and mRNA has been
previously detected 3-8 days postchallenge, establishing
that TNF is increased before both the early (2 day) and
late (i6 day) MIP-ia peaks [i2, 21]. Supporting these
results, normal lavage cells from CBA/J mice express
MIP-la protein after stimulation with TNF in vitro. Re-
cent experiments in our laboratories suggest that TNF is
a stimulus for MIP-ia expression in vivo. In CBA/J mice
treated with soluble TNF receptor we detected an 80%
reduction of MIP-ia protein 2 days postbleomycin chal-
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lenge, a time corresponding to the first MIP-la expres-
sion peak (unpublished observations). In addition, mice
treated with soluble TNF receptor at 4 days postbleomy-
cm administration (after the first MIP-ia peak) demon-
strated a modest 35% reduction in MIP-ia at day iO
postchallenge, a time point corresponding to the second
MIP-la expression peak. However, previous data have
established that IL-i is a potent stimulus for MIP-ia in
vitro [43, 46]. Because TNF can induce IL-i, TNF may
stimulate MIP-ia expression indirectly. Studies are under-
way in our lab to evaluate the potential costimulatory role
of IL-i in TNF-mediated MIP-la production during the
pulmonaiy response to bleomycin challenge.
Recent studies in the chronic schistosoma granuloma
model support the notion of a TNF-mediated MIP-ia
pathway. Similar to the bleomycin pulmonary lesion, pni-
mary liven schistosoma granuloma formation may be at-
tenuated with either anti-MIP-la or anti-TNF antibody
therapy [52]. Interestingly, IL-i receptor antagonist pro-
tein is also elevated in the primary granuloma lesion,
suggesting a lesser role for IL-i and a greater role for
TNF in the initiation of the chronic granulomatous re-
sponse [57]. In summary, the cytokine expression pat-
terns observed in the primary schistosoma granuloma,
along with data from the bleomycin model, support the
contention of a TNF-mediated MIP-la pathway for the
initiation of chronic inflammatory lesions.
Chronic inflammatory processes, like the bleomycin-in-
duced lesion, are postulated to involve a macrophage-lym-
phocyte-fibroblast cellular axis responsible for the
initiation and maintenance of chronic inflammation. In
the bleomycin model inhibition of lymphocyte-, macro-
phage-, on fibnoblast-mediated inflammatory mechanisms
attenuates fibrosis, the hallmark of the lesion. It may be
postulated that these cell types activate one another, initi-
ating and maintaining the chronic lesion via secretion of
soluble proimiflammatory substances. The data discussed
in this review indicate that macrophages, lymphocytes,
and fibroblasts both produce and are modulated by MCP-
1 and MIP-la, suggesting a role for C-C chemokines in
this putative cellular network. In this context, future ex-
periments svill examine the specific roles of MCP-i, MIP-
ia, and additional chemokines in lung fibrosis, leukocyte
recruitment, and maintenance of the chronic bleomycmn-
induced lesion. Regardless of the specifics of this cellular
network, C-C chemokines are expressed and regulate
chronic lung injury during the response to bleomycin
challenge.
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